NASDAQ:GDTC

CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit

Retrieved on: 
Thursday, August 17, 2023
August 24th Movement, Cytomics, Tutoring

Singapore, Singapore--(Newsfile Corp. - August 17, 2023) - CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company") announced today it will be presenting at the August 24th, 2023 virtual Investor Summit.

Key Points: 

Singapore, Singapore--(Newsfile Corp. - August 17, 2023) - CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company") announced today it will be presenting at the August 24th, 2023 virtual Investor Summit.

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

Retrieved on: 
Tuesday, August 1, 2023
GMP, China National Intellectual Property Administration, Patent, Antigen, CNIPA, Partnership, IPSC, NKT, STAR, National University Hospital, Clinical trial, Cell, Immunotherapy, CN, NUH, Agency for Science, Technology and Research, Hematological Cancer Research Investment and Education Act, Biological patents in the United States, Risk, A*STAR, Cytomics, Blood, Agency, Cancer, Same, Outline of health sciences, Health Sciences Authority, T, HSA, NKG2D, Pharmaceutical industry, Vaccine, Science, Research

SINGAPORE, Aug. 1, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, which is exclusively licensed from the Agency for Science, Technology and Research (A*STAR), has been granted a patent by the China National Intellectual Property Administration (CNIPA).

Key Points: 
  • The Company holds an exclusive, worldwide license, for use in immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • CytoMed's CAR-γδ T cell technology has been developed as an investigational cancer therapy to target NKG2D ligands, a type of stress-induced cancer antigens.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive a novel synthetic γδ NKT cells for the treatment of various types of cancers.
  • A patent for this proprietary technology has already been granted in Japan, and this asset is under preclinical development.

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US

Retrieved on: 
Thursday, July 6, 2023
Yee, Patent, Antigen, Cytomics, IPSC, NKT, STAR, National University Hospital, Alberta Enterprise Group, United States patent law, Innovation, Research, Immunotherapy, NUH, Assistant, CAR, Cancer, Hematological Cancer Research Investment and Education Act, Gamma delta T cell, Biological patents in the United States, Patient, Risk, A*STAR, Same, Outline of health sciences, Health Sciences Authority, Therapy, T, HSA, NKG2D, Vaccine

Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.

Key Points: 
  • Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.
  • CytoMed holds an exclusive, worldwide license, for use on immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive γδ NKT cells for cancer treatments.
  • A patent for this proprietary technology has already been granted in Japan and this asset is under preclinical development.